Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The cardiac mitochondrial ATP-sensitive potassium channel (mitoKATP) is a critical protein complex located in the inner mitochondrial membrane that plays a pivotal role in cardioprotection and mitochondrial volume regulation. It is a primary mediator of ischemic preconditioning, a phenomenon where brief, non-lethal periods of ischemia protect the heart against subsequent severe ischemic injury (O'Rourke, 2004; PubMed: 15082356). The molecular identity of mitoKATP was recently identified as a complex consisting of the pore-forming subunit CCDC51 (MITOK) and the regulatory subunit ABCB8 (MITOSUR) (Paggio et al., 2019; Nature: 572(7771)). Activation of the channel by pharmacological agents like diazoxide leads to potassium influx into the mitochondrial matrix, causing mild membrane depolarization and the release of signaling reactive oxygen species (ROS) (Garlid & Halestrap, 2012; PubMed: 22227311). These ROS act as secondary messengers to activate survival signaling pathways that inhibit the opening of the mitochondrial permeability transition pore (mPTP), preventing cardiomyocyte death. While mitoKATP is a highly attractive therapeutic target for myocardial infarction and heart failure, achieving drug selectivity to avoid off-target effects on sarcolemmal and pancreatic KATP channels remains a significant challenge in drug development.
Opening of the channel facilitates potassium ion entry into the mitochondrial matrix, causing mild depolarization and ROS-mediated signaling that prevents mitochondrial permeability transition pore (mPTP) opening.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cardiac mitochondrial ATP-sensitive potassium channel (mitoKATP) (mitoKATP).